92 patents
Page 4 of 5
Utility
Valbenazine salts and polymorphs thereof
30 Nov 20
Provided herein are salts of (S)-2-amino-3-methyl-butyric acid (2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]-isoquinolin-2-yl ester in amorphous and crystalline forms, and processes of preparation, and pharmaceutical compositions thereof.
Kevin McGee, Scott E. Zook, Andrew Carr, Thierry Bonnaud, Bin-Feng Li
Filed: 11 Jun 20
Utility
Valbenazine salts and polymorphs thereof
23 Nov 20
Provided herein are salts of (S)-2-amino-3-methyl-butyric acid (2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,l-a]isoquinolin-2-yl ester in amorphous and crystalline forms, and processes of preparation, and pharmaceutical compositions thereof.
Kevin McGee, Scott E. Zook, Andrew Carr, Thierry Bonnaud, Bin-Feng Li
Filed: 11 Jun 20
Utility
Methods for the Administration of Certain VMAT2 Inhibitors
18 Nov 20
Provided are methods of administering a vesicular monoamine transport 2 (VMAT2) inhibitor chosen from valbenazine, or a pharmaceutically acceptable salt and/or isotopic variant thereof, to a patient in need thereof.
Grace S. Liang, Christopher F. O`Brien, Dao Tuyet Thai-Cuarto
Filed: 2 Aug 20
Utility
SYNTHETIC METHODS FOR PREPARATION OF (S)-(2R,3R,11BR)-3-ISOBUTYL-9,10-DIMETHOXY-2,3,4,6,7,11B-HEXAHYDRO-1H-PYRIDO[2,1,-A]lSOQUINOLIN-2-YL 2-AMINO-3-METHYLBUTANOATE DI(4-METHYLBENZENESULFONATE)
4 Nov 20
Provided herein are processes for the preparation of (S)-(2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-pyrido[2,1-a]isoquinolin-2-yl 2-amino-3-methylbutanoate di(4-methylbenzenesulfonate), or a solvate, hydrate, or polymorph thereof.
Kevin McGee, Bin-Feng Li
Filed: 14 Jul 20
Utility
SYNTHETIC METHODS FOR PREPARATION OF (S)-(2R,3R,11BR)-3-ISOBUTYL-9,10-DIMETHOXY-2,3,4,6,7,11B-HEXAHYDRO-1H-PYRIDO[2,1,-A]lSOQUINOLIN-2-YL 2-AMINO-3-METHYLBUTANOATE DI(4-METHYLBENZENESULFONATE)
4 Nov 20
Provided herein are processes for the preparation of (S)-(2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-pyrido[2,1-a]isoquinolin-2-yl 2-amino-3-methylbutanoate di(4-methylbenzenesulfonate), or a solvate, hydrate, or polymorph thereof.
Kevin McGee, Bin-Feng Li
Filed: 14 Jul 20
Utility
SYNTHETIC METHODS FOR PREPARATION OF (S)-(2R,3R,11BR)-3-ISOBUTYL-9,10-DIMETHOXY-2,3,4,6,7,11B-HEXAHYDRO-1H-PYRIDO[2,1,-A]lSOQUINOLIN-2-YL 2-AMINO-3-METHYLBUTANOATE DI(4-METHYLBENZENESULFONATE)
4 Nov 20
Provided herein are processes for the preparation of (S)-(2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-pyrido[2,1-a]isoquinolin-2-yl 2-amino-3-methylbutanoate di(4-methylbenzenesulfonate), or a solvate, hydrate, or polymorph thereof.
Kevin McGee, Bin-Feng Li
Filed: 14 Jul 20
Utility
SYNTHETIC METHODS FOR PREPARATION OF (S)-(2R,3R,11BR)-3-ISOBUTYL-9,10-DIMETHOXY-2,3,4,6,7,11B-HEXAHYDRO-1H-PYRIDO[2,1,-A]lSOQUINOLIN-2-YL 2-AMINO-3-METHYLBUTANOATE DI(4-METHYLBENZENESULFONATE)
4 Nov 20
Provided herein are processes for the preparation of (S)-(2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-pyrido[2,1-a]isoquinolin-2-yl 2-amino-3-methylbutanoate di(4-methylbenzenesulfonate), or a solvate, hydrate, or polymorph thereof.
Kevin McGee, Bin-Feng Li
Filed: 14 Jul 20
Utility
Methods for the Administration of Certain VMAT2 Inhibitors
28 Oct 20
Provided are methods of administering a vesicular monoamine transport 2 (VMAT2) inhibitor chosen from valbenazine and (+)-a-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-ol, or a pharmaceutically acceptable salt and/or isotopic variant thereof to a patient in need thereof wherein the patient is being treated with a strong cytochrome P450 3A4 (CYP3A4) inducer.
Christopher F. O`Brien, Haig P. Bozigian
Filed: 9 Oct 17
Utility
Valbenazine Salts and Polymorphs Thereof
28 Oct 20
Provided herein are salts of (S)-2-amino-3-methyl-butyric acid (2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-yl ester in amorphous and crystalline forms, and processes of preparation, and pharmaceutical compositions thereof.
Kevin McGee, Scott E. Zook, Andrew Carr, Thierry Bonnaud
Filed: 11 Jun 20
Utility
Valbenazine Salts and Polymorphs Thereof
28 Oct 20
Provided herein are salts of (S)-2-amino-3-methyl-butyric acid (2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-yl ester in amorphous and crystalline forms, and processes of preparation, and pharmaceutical compositions thereof.
Kevin McGee, Scott E. Zook, Andrew Carr, Thierry Bonnaud
Filed: 11 Jun 20
Utility
Valbenazine Salts and Polymorphs Thereof
28 Oct 20
Provided herein are salts of (S)-2-amino-3-methyl-butyric acid (2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-yl ester in amorphous and crystalline forms, and processes of preparation, and pharmaceutical compositions thereof.
Kevin McGee, Scott E. Zook, Andrew Carr, Thierry Bonnaud
Filed: 11 Jun 20
Utility
High Dosage Valbenazine Formulation and Compositions, Methods, and Kits Related Thereto
2 Sep 20
Solid pharmaceutical compositions with high drug loading are provided.
Richard Alexander Moore, Jr., Gregory A. McClelland, Christopher F. O`Brien
Filed: 17 Sep 18
Utility
Methods for the Administration of Certain VMAT2 Inhibitors
26 Aug 20
Provided are methods of administering a vesicular monoamine transport 2 (VMAT2) inhibitor chosen from valbenazine and (+)-a-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-ol, or a pharmaceutically acceptable salt and/or isotopic variant thereof, to a patient in need thereof wherein the patient is also being administered a strong cytochrome P450 3A4 (CYP3A4) inhibitor.
Christopher F. O`Brien, Haig P. Bozigian
Filed: 7 May 20
Utility
Methods for the Administration of Certain VMAT2 Inhibitors
26 Aug 20
Provided are methods of administering a vesicular monoamine transport 2 (VMAT2) inhibitor chosen from valbenazine and (+)-α-3-isobutyl-9,10-dimethoxy-1, 3,4, 6,7,11 b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-ol, or a pharmaceutically acceptable salt and/or isotopic variant thereof, to a patient in need thereof wherein the patient is a CYP2D6 poor metabolizer.
Christopher F. O`Brien, Haig P. Bozigian
Filed: 7 May 20
Utility
Methods for the Administration of Certain VMAT2 Inhibitors
26 Aug 20
Provided are methods of administering a vesicular monoamine transport 2 (VMAT2) inhibitor chosen from valbenazine and (+)-α-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-ol, or a pharmaceutically acceptable salt and/or isotopic variant thereof, to a patient in need thereof wherein the patient is also being administered a strong cytochrome P450 2D6 (CYP2D6) inhibitor.
Christopher F. O`Brien, Haig P. Bozigian
Filed: 7 May 20
Utility
Methods for the Administration of Certain VMAT2 Inhibitors
26 Aug 20
Provided are methods of administering a vesicular monoamine transport 2 (VMAT2) inhibitor chosen from valbenazine and (+)-α-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-ol, or a pharmaceutically acceptable salt and/or isotopic variant thereof, to a patient in need thereof wherein the patient has mild, moderate, or severe hepatic impairment.
Christopher F. O`Brien, Haig P. Bozigian
Filed: 7 May 20
Utility
Methods for the Administration of Certain VMAT2 Inhibitors
26 Aug 20
Provided are methods of administering a vesicular monoamine transport 2 (VMAT2) inhibitor chosen from valbenazine and (+)-α-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-ol, or a pharmaceutically acceptable salt and/or isotopic variant thereof, to a patient in need thereof wherein the patient is also being administered digoxin.
Christopher F. O`Brien, Haig P. Bozigian
Filed: 10 May 20
Utility
[9,10-DIMETHOXY-3-(2-METHYLPROPYL)-1H,2H,3H,4H,6H,7H,11BH-PYRIDO-[2,1-A]ISOQUINOLIN-2-YL]METHANOL and Compounds, Compositions and Methods Relating Thereto
19 Aug 20
Neil Ashweek, Nicole Harriott
Filed: 21 Jan 20
Utility
Processes for the Preparation of Uracil Derivatives
12 Aug 20
The present invention relates to processes and intermediates for preparing Gonadotropin-Releasing Hormone (GnRH) receptor antagonists of structure (VI); and stereoisomers and pharmaceutically acceptable salts thereof.
Donald J. GALLAGHER, Laszlo R. TREIBER, Robert Michael HUGHES, Onorato CAMPOPIANO, Peng WANG, Yuxin ZHAO, Shine K. CHOU, Michael Allen OUELLETTE, Donald Nicholas HETTINGER
Filed: 9 Jan 20
Utility
Substituted triazoles and methods relating thereto
10 Aug 20
Neil J. Ashweek, John P. Williams, Deborah Slee, Manisha Moorjani
Filed: 28 Oct 18